Arkless Kate, Argunhan Fulye, Brain Susan D
Section of Vascular Biology & Inflammation, School of Cardiovascular Medicine & Sciences, BHF Centre for Cardiovascular Sciences, King's College London, London, UK.
Handb Exp Pharmacol. 2019;255:1-12. doi: 10.1007/164_2018_129.
Calcitonin gene-related peptide (CGRP) was discovered over about 35 years ago through molecular biological techniques. Its activity as a vasodilator and the proposal that it was involved in pain processing were then soon established. Today, we are in the interesting situation of having the approval for the clinical use of antagonists and antibodies that have proved to block CGRP activities and benefit migraine. Despite all, there is still much to learn concerning the relevance of the vasodilator and other activities as well as further potential applications of CGRP agonists and blockers in disease. This review aims to discuss the history and present knowledge and to act as an introductory chapter in this volume.
降钙素基因相关肽(CGRP)大约在35年前通过分子生物学技术被发现。其作为血管舒张剂的活性以及它参与疼痛处理的观点随后很快得到证实。如今,我们面临着一种有趣的情况,即已经批准了一些拮抗剂和抗体用于临床,这些拮抗剂和抗体已被证明能够阻断CGRP的活性并对偏头痛有益。尽管如此,关于血管舒张剂及其他活性的相关性以及CGRP激动剂和阻滞剂在疾病中的进一步潜在应用,仍有许多有待了解的地方。本综述旨在讨论其历史和当前的知识,并作为本卷的引言章节。